Profile
Susan Wong has been Vice President of Finance and Chief Accounting Officer for Tercica, Inc. since March 2006.
She was an Acting Chief Financial Officer of Tercica from June 2005 to March 2006 and Vice President-Finance and Controller from January 2004 to March 2006.
Ms. Wong was Senior Vice President and Corporate Controller of innoVentry Corp.
from August 2000 to October 2001 and Vice President and Corporate Controller of Ocular Sciences, Inc. from September 1993 to July 2000.
She was Director of Corporate Accounting and Financial Reporting and Planning & Analysis for Vanstar, Inc. from September 1989 to 1993.
Ms. Wong held various positions in the Audit Group at Coopers & Lybrand from August 1985 to August 1989.
She is a Certified Public Accountant and received a BS degree in Finance and Accounting from the University of California.
Former positions of Susan Wong
| Companies | Position | End |
|---|---|---|
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Comptroller/Controller/Auditor | 2014-02-02 |
| Innoventry, Inc. | Comptroller/Controller/Auditor | 2001-09-30 |
Ocular Sciences, Inc.
 Ocular Sciences, Inc. Medical SpecialtiesHealth Technology Ocular Sciences, Inc. was manufacturer and marketer of contact lenses for annual and disposable replacement regimens. It used to manufacture soft contact lenses such as disposable toric, cosmetic, aspheric, multi-focal, sports and extended-wear lenses. Ocular sciences was marketing their products exclusively to eye care practitioners, both in private practice and retail chains. The company was founded in 1983 and was headquartered in Concord, CA. | Comptroller/Controller/Auditor | 2000-06-30 |
Vanstar Corp.
 Vanstar Corp. Miscellaneous Commercial ServicesCommercial Services Vanstar Corp. is a gold exploration company with properties located in northern Quebec. Vanstar also owns 100% of the Felix property under development in the Chicobi group and 100% of Amanda, a 7,679 ha property located on the Auclair formation with historic gold showings up to 12.1 g/t Au over 3 meters. The company is based in Canada. The American company owns a 25% interest in the Nelligan project, which won the "Discovery of the Year" award at the 2019 Quebec Mineral Exploration Association Xplor Gala. Vanstar was acquired by InaCom Corp. on February 17, 1999 for $436.07 million. | Comptroller/Controller/Auditor | 1992-12-31 |
Training of Susan Wong
| University of California, Berkeley | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Vanstar Corp.
Vanstar Corp. Miscellaneous Commercial ServicesCommercial Services Vanstar Corp. is a gold exploration company with properties located in northern Quebec. Vanstar also owns 100% of the Felix property under development in the Chicobi group and 100% of Amanda, a 7,679 ha property located on the Auclair formation with historic gold showings up to 12.1 g/t Au over 3 meters. The company is based in Canada. The American company owns a 25% interest in the Nelligan project, which won the "Discovery of the Year" award at the 2019 Quebec Mineral Exploration Association Xplor Gala. Vanstar was acquired by InaCom Corp. on February 17, 1999 for $436.07 million. | Commercial Services |
Ocular Sciences, Inc.
Ocular Sciences, Inc. Medical SpecialtiesHealth Technology Ocular Sciences, Inc. was manufacturer and marketer of contact lenses for annual and disposable replacement regimens. It used to manufacture soft contact lenses such as disposable toric, cosmetic, aspheric, multi-focal, sports and extended-wear lenses. Ocular sciences was marketing their products exclusively to eye care practitioners, both in private practice and retail chains. The company was founded in 1983 and was headquartered in Concord, CA. | Health Technology |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
| Innoventry, Inc. |
- Stock Market
- Insiders
- Susan Wong
